COVID-19 Therapeutics Strategy: Commission identifies five promising candidate therapeutics
Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.”
Of course Ivermectin is not mentioned at all.
"European Health Union in action" my ass....
"The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are:
A new COVID-19 indication for existing medicines:
baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment
Newly developed monoclonal antibodies under rolling review - a regulatory tool to speed up the assessment of a promising medicine during a public health emergency:
combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review
combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review
regdanvimab from Celltrion: under rolling review
sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review"
All "new" drugs, obviously going to be high cost for us, high profit for big Pharma.
Low cost Ivermectin won't lead to high profits for big Pharma
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3299
Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.”
Of course Ivermectin is not mentioned at all.
"European Health Union in action" my ass....
"The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are:
A new COVID-19 indication for existing medicines:
baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment
Newly developed monoclonal antibodies under rolling review - a regulatory tool to speed up the assessment of a promising medicine during a public health emergency:
combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review
combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review
regdanvimab from Celltrion: under rolling review
sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review"
All "new" drugs, obviously going to be high cost for us, high profit for big Pharma.
Low cost Ivermectin won't lead to high profits for big Pharma
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3299